General Gastro News Articles

Gastro

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Gisbert JP et al. – Certolizumab differs from infliximab and adalimumab in that it is a Fab fragment of an antitumor necrosis factor alpha monoclonal antibody, and therefore it may not be necessary to stop certolizumab in the third trimester. The use of infliximab is probably compatible with breast–feeding.

Related Articles

Novel Diagnostic and Prognostic Modalities in Inflammatory Bowel Disease
Gastroenterology Clinics of North America, 11/17/09    Relevance Score: 83%

Pregnancy and Inflammatory Bowel Disease
Gastroenterology Clinics of North America, 11/17/09    Relevance Score: 83%

Pathogenesis of inflammatory bowel disease (IBD)
The Internet Journal of Gastroenterology, 11/13/09    Relevance Score: 83%

Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study
The Lancet, 11/09/09    Relevance Score: 83%

Genetics of inflammatory bowel disease: implications for disease pathogenesis and natural history
Expert Review of Gastroenterology & Hepatology, 10/13/09    Relevance Score: 83%

Today in Inflammatory Bowel Dz...keeping you current

Appendiceal Mucocele Detected under Treatment of Ulcerative Colitis
Case Reports in Gastroenterology, 11/25/09

Pyoderma Gangrenosum in Crohn's Disease: Unusual Presentation and Management
Case Reports in Gastroenterology, 11/25/09

Influence of NFkB inhibitors on IL-1beta-induced chemokine CXCL8 and -10 expression levels in intestinal epithelial cell lines: glucocorticoid ineffectiveness and paradoxical effect of PDTC
International Journal of Colorectal Disease, 11/24/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address